Business
Posting of Annual Report and
Posting of Annual Report and.
About this update from Gunsynd Plc
[{"type":"text","content":"\n RNS Number : 4840Z Syntopix Group plc 14 January 2011 \n \n\n \n \n\n\n\n\nPress Release \n\n\n14 January 2011\n\n\n\n\n \nSyntopix Group plc\n(\"Syntopix\" or \"the Company\")\n \nPosting of Annual Report and notice of AGM\n \n\nSyntopix Group plc (AIM:SYN), the company focused on topical antimicrobial innovations for products in the medicine and consumer healthcare markets, confirms that the Annual Report and Accounts for the year ended 31 July 2010, the Notice of the Annual General Meeting and the Form of Proxy were posted to shareholders on 14 December 2010.\n \nThe Company's Annual General Meeting is to be held on Thursday 20 January 2011 at the offices of IP Group Plc 24 Cornhill, London, EC3V 3ND.\n \n- Ends -\n \nFor further information, please contact:\n \n\n\n\n\nSyntopix Group plc\n\n\n\n\n\n\n\nDr Stephen Jones, Chief Executive Officer\n\n\n+44 (0)845 125 9204\n\n\n\n\nTom Bannatyne, Chairman\n\n\nwww.syntopix.com\n\n\n\n\n \n\n\n\n\nZeus Capital Ltd\n\n\n\n\n\n\n\nAlex Clarkson/Tom Rowley\n\n\nTel: +44(0)161 831 1512 \n\n\n\n\n\n\n\nwww.zeuscapital.co.uk\n\n\n\n\n \n\n\n\n\nXCAP Securities Plc\n\n\n\n\n\n\n\nJohn Grant/ David Newton\n\n\nTel: +44(0) 207 101 7070 \n\n\n\n\n\n\n\nwww.xcapgroup.co.uk\n\n\n\n\n \nMedia enquiries:\n\n\n\n\nAbchurch Communications\n\n\n\n\n\n\n\nSarah Hollins / Simone Elviss / Claire Dickinson\n\n\nTel: +44 (0) 20 7398 7714\n\n\n\n\[email protected] \n\n\nwww.abchurch-group.com\n\n\n\n\n\nNotes to editors\nAbout Syntopix Group\nSyntopix is a specialised research and development company, focusing on topical antimicrobial innovations for the cosmetic, consumer healthcare and pharmaceutical markets. The Group was founded in 2003 as a spin-out from the University of Leeds by Dr Jon Cove and Dr Anne Eady, two of the world's leading experts in skin microbiology.\n \nSyntopix combines scientific excellence with an understanding of consumer need to identify and develop innovative compounds which have clinical efficacy and proven benefits for the treatment of acne, gingivitis and body odour. \n \nThe Group has a robust research pipeline, with a growing library of over 2,700 compounds (with establis...